Prescient Therapeutics Advances PTX-100 to Phase 2 in Fight Against T-Cell Lymphoma
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics Ltd (ASX: PTX) initiates a Phase 2a clinical trial for PTX-100 in cutaneous...
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a...
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased...
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt...
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter and products...
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.